--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-056303" form_type: "8-K" ticker: "ELVN" cik: "0001672619" company_name: "Enliven Therapeutics, Inc." filed_at: "2023-03-01T23:59:59+00:00" generated_at: "2026-06-18T18:16:10.968403+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.95 calibrated_materiality_score: 0.95 confidence: "high" source: SEC EDGAR --- # Imara completes reverse merger with Enliven; combined company to trade as ELVN ## Summary - Merger closed Feb 23, 2023; exchange ratio ~0.2951; ~41.1M shares outstanding post-merger. - Former Enliven shareholders own ~84% of combined company; Imara shareholders ~16%. - Imara shareholders receive one CVR per share for potential payments from tovinontrine sale to Cardurion. - New leadership: Sam Kintz (CEO), Benjamin Hohl (CFO); prior Imara CEO and CFO resigned with severance. - Auditor changed from EY to Deloitte; 1-for-4 reverse stock split; ticker changes to ELVN. ## SEC filing metadata - accession: 0001193125-23-056303 - form_type: 8-K - ticker: ELVN - cik: 0001672619 - company_name: Enliven Therapeutics, Inc. - filed_at: 2023-03-01T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.95 - calibrated_materiality_score: 0.95 - confidence: high - sec_items: 1.01, 2.01, 5.02, 3.03, 4.01, 5.01, 5.03, 5.05, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/d464771d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-056303 - JSON: https://secwatch.observer/filing/0001193125-23-056303.json - Plain text: https://secwatch.observer/filing/0001193125-23-056303.txt ## Key facts - Auditor Changes Enliven Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor. - Action: engagement - Auditor: Deloitte & Touche LLP source text: On February 23, 2023, following the completion of the Merger, the Audit Committee approved the appointment of Deloitte as the Company’s independent registered public accounting firm, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Auditor Changes Enliven Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor. - Action: dismissal - Auditor: Ernst & Young LLP - Successor: Deloitte & Touche LLP source text: On February 23, 2023, following the completion of the Merger, EY was informed that the Audit Committee of the Board (the “ Audit Committee ”) approved EY’s dismissal as the Company’s independent registered public accounting firm, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Rahul D. Ballal, Ph.D. resigned as President and Chief Executive Officer at Enliven Therapeutics, Inc.. - Action: resigned - Role: President and Chief Executive Officer source text: On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Mark Chin resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change David Bonita, M.D. resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Edward Conner, M.D. resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Barbara J. Dalton, Ph.D resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Laura Williams, M.D., MPH resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Carl Goldfischer, M.D. resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change Michael P. Gray resigned as Chief Financial Officer and Chief Operating Officer at Enliven Therapeutics, Inc.. - Action: resigned - Role: Chief Financial Officer and Chief Operating Officer source text: On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Executive change David M. Mott resigned as Director at Enliven Therapeutics, Inc.. - Action: resigned - Role: Director source text: David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Governance Changes Enliven Therapeutics, Inc.: Filed Stock Split Amendment to effect reverse stock split and common stock reduction, and filed Name Change Amendment to change company name to Enliven Therapeutics, Inc (effective 2023-02-23). - Change: charter amendment - Effective: 2023-02-23 source text: On February 23, 2023, the Company filed the Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. on February 23, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - Governance Changes Enliven Therapeutics, Inc.: Adopted a new Code of Business Conduct and Ethics, superseding the pre-Merger code (effective 2023-02-23). - Change: code of ethics - Effective: 2023-02-23 source text: In connection with the Merger, the Board adopted a new Code of Business Conduct and Ethics (the “ Code of Conduct ”) on February 23, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm - M&A Transactions Enliven Therapeutics, Inc. underwent a change of control involving Former Enliven (formerly Enliven Therapeutics, Inc.) (closed 2023-02-23). - Action: change of control - Counterparty: Former Enliven (formerly Enliven Therapeutics, Inc.) - Closing: 2023-02-23 source text: On February 23, 2023, the Company completed its business combination with Former Enliven in accordance with the terms of the Agreement and Plan of Merger, dated as of October 13, 2022 evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523056303/0001193125-23-056303-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.